Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 244
Tipo Título / Nombre Autor(es) Año
Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, Moreno MJ, Martínez-Carballeira D, García-Cadenas I, Vives S, Ribera J, González-Campos J, Diaz-Beyá M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermúdez A, Vall-Llovera F, Martínez P, Amigo ML, Bergua JM, Calbacho M, Hernández-Rivas JM, Monsalvo S, Novo A, Cervera M, García-Guiñón A, Junca J, Ciudad J, Orfao A, Ribera JM 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG) Bergua J, Martínez Cuadrón D, Boluda B, Martínez P, Rodríguez Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Carretero C, Jiménez Ubieto A, Prieto J, Díaz Beyá M, Brunet S, Benavente C, Pérez Simón JA, Suárez Varela S, Morcardó F, Sanz MA, Montesinos P 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM 2018
A subset of AML patients shows different quimiosensitivy ex vivo profiles to anthracyclines and its combination with cytarabine; could precision medicine be the key selection criterion? Martínez Cuadrón D, Ballesteros J, Martínez López J, Hernández P, Primo D, Gorrochategui J, Rojas JL, Bergua JM, Tormo M, Serrano J, González A, Pérez de Oteyza J, Vives S, Vidriales B, Herrera P, Vera JA, López A, Fuente A de la, Amador ML, Hernández Rivas JA, Fernández MA, Cerveró CJ, Morillo D, Megías JE, Sanz M, Montesinos P 2018
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E, PETHEMA Group, Spanish Society of Hematology 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E, PETHEMA Group 2018
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A, PETHEMA Group, Spanish Society of Hematology 2018